Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
Ryota Ito,Masato Kawamura,Takumi Sato,Shigeru Fujimura
DOI: https://doi.org/10.2147/IDR.S382142
2022-10-10
Infection and Drug Resistance
Abstract:Ryota Ito, Masato Kawamura, Takumi Sato, Shigeru Fujimura Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, Sendai, Miyagi, Japan Correspondence: Ryota Ito, Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, 4-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi, 981-8558, Japan, Tel +81-22-727-0169, Fax +81-22-727-0176, Email Purpose: Cefmetazole (CMZ), a cephamycin antibiotic, is primarily used as a definitive therapy for Extended Spectrum β-Lactamase (ESBL)-producing Escherichia coli infections. However, the mechanism of CMZ resistance in E. coli is still unknown. To elucidate the resistance mechanism and to determine combined drugs for prevention of resistance acquisition. Methods: Clinical isolates of 14 ESBL-producing E. coli and non-producing 12 isolates were used in in vitro testing of CMZ resistance acquisition. After 10-day of CMZ exposure (1st subculture), these strains were incubated in an antibacterial-free medium for 14-day. These strains were again exposed to CMZ for 10-day (2nd subculture) and confirmed for changes in MIC. For each strain detected after 1st subculture, each mRNA expression level of porin, chromosomal ampC , and drug-efflux pump was measured using real-time RT-PCR. Relebactam (REL) has the potency to recover antimicrobial activity against carbapenem-resistant Enterobacterales that has porin deficiency. REL was added to the CMZ dilution series, and MIC changes and those of porin were confirmed. Results: Of these 26 strains, 15 strains (57.7%) acquired resistance after 1st subculture, but after passage culture on the antibacterial-free medium, 11 strains recovered susceptibility. These 11 strains showed resistance after 2nd subculture. The expression levels of ompF and ompC were significantly decreased in these strains ( P < 0.05). When REL was added, all strains suppressed resistance acquisition after 1st subculture. The mechanism was the activation of ompF . Conclusion: Our results showed that the mRNA expression levels of genes encoding porin were decreased in the strains that acquired resistance due to CMZ exposure, and that ompF and ompC in particular were thought to be involved in the acquisition of resistance. The CMZ acquisition of resistance was also suppressed by the concomitant use of REL and actually suppressed the decrease in mRNA expression in ompF . It was confirmed that porin reactivated by REL. Keywords: cefmetazole, porin, relebactam, extended spectrum β-lactamase, ESBL, Escherichia coli Escherichia coli is the main causative organism of urinary tract infection. 1 The intractable cases due to this pathogen increase; and two reasons are suggested recently. Firstly, biofilm formation attracts attention, and biofilms have 3-dimensional structures which formed on solid surfaces such as indwelling urinary catheters and other devices. Eradication of the biofilm-formed strain is extremely difficult because they function to protect the bacterial cell from antimicrobial agents. 2 Conventionally, though the sterilization by the silver catalyst has been investigated as coping, most of enough effects are not shown. 3,4 The sterilization technology using the new metal catalyst was reported recently and the clinical application is expected. 5 The second is the emergence of various antimicrobial resistance E. coli . Extended-spectrum-lactamase (ESBL)-producing strain in particular rages worldwide, and is generally resistant to most penicillin and cephalosporin. 6 In the United Kingdom, the strain which further acquired resistance in ciprofloxacin and trimethoprim/sulfamethoxazole was isolated at high frequency. 7 ESBL-producing strain is detected in the world recently, the strain in E. coli of urinary tract origin was reported to be 17.9% in Europe in 2018, and 24% in Japan in 2015. 8,9 Such ESBL-producing E. coli has drawn attention as a cause for not only nosocomial infections but also community-acquired infection. 10,11 The Infectious Diseases Society of America (IDSA) guidelines for resistant bacteria treatment recommend such as carbapenem, quinolone, and trimethoprim/sulfamethoxazole as antibiotics to treat infections by ESBL-producing bacteria. 12 Meanwhile in Japan, aside from carbapenem, β-lactam/β-lactamase inhibitor combinations such as tazobactam/piperacillin and tazobactam/ceftolozane are available for use, but the cephamycin antibiotic, cefmetazole (CMZ), is mainly used. Generally, the first-line drug in serious infections such as sepsis, i -Abstract Truncated-
pharmacology & pharmacy,infectious diseases